Purpose of this Study
We are doing this study to find out how an experimental vaccine (pING-hHER3FL) works in your body and against your cancer.
Who Can Participate?
Eligibility
People who have gotten previous treatment with surgery and/or chemotherapy + radiation for one of the following cancers:<ul>
<li>Breast</li>
<li>Colon</li>
<li>Lung</li>
<li>Prostate</li>
<li>Ovarian</li>
<li>Cervical</li>
<li>Endometrial</li>
<li>Gastric (stomach)</li>
<li>Pancreatic</li>
<li>Bladder</li>
<li>Head and neck</li>
<li>Liver</li>
<li>Esophageal</li></ul>
For more information about who can join this study, please contact the study team at felecia.walton@duke.edu.
<li>Breast</li>
<li>Colon</li>
<li>Lung</li>
<li>Prostate</li>
<li>Ovarian</li>
<li>Cervical</li>
<li>Endometrial</li>
<li>Gastric (stomach)</li>
<li>Pancreatic</li>
<li>Bladder</li>
<li>Head and neck</li>
<li>Liver</li>
<li>Esophageal</li></ul>
For more information about who can join this study, please contact the study team at felecia.walton@duke.edu.
What is Involved?
If you choose to join this study, you will:<ul>
<li>Get the study vaccine three times over 8 weeks</li>
<li>Have occasional blood draws for 5 years</li>
<li>Have a biopsy to collect tumor tissue, if necessary</li></ul>
<li>Get the study vaccine three times over 8 weeks</li>
<li>Have occasional blood draws for 5 years</li>
<li>Have a biopsy to collect tumor tissue, if necessary</li></ul>
Study Details
Full Title
ASSESSING THE IMMUNOGENICITY OF pING-hHER3FL VACCINE IN PATIENTS WITH RESECTED MALIGNANCIES
Principal Investigator
Michael
Morse
Protocol Number
PRO00104093
NCT ID
NCT03832855
Phase
I
Enrollment Status
Open to Enrollment